An agreement would invite government scrutiny on both sides of the pond.
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Annelise Capossela/Axios
AstraZeneca has had merger talks with Bristol-Myers Squibb, according to the Financial Times.
Why it matters: A tie-up would create the world's fourth most valuable drugmaker, with around $400 billion in combined market cap.
AstraZeneca, Bristol Myers are in talks about merger — report
AstraZeneca in talks over £300bn mega-merger with US rival – reports
AstraZeneca said to have explored Bristol Myers merger | Fortune
UK's AstraZeneca eyeing $400b merger, report says
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger - AstraZeneca (NYSE:AZN)
AstraZeneca, BMS discuss $400B pharma mega-deal
Pharma giants AstraZeneca, Bristol Myers Squibb in talks on $512 billion megadeal: Report
AstraZeneca ‘in talks to create £300bn pharmaceutical giant’
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers
